TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced.
“The highest quality medical imaging provided by Imaging Endpoints is one more weapon in TD2’s arsenal,” said Dr. Stephen Gately, president of TD2, which assists drug developers in navigating the regulatory maze involved in the successful completion of clinical trials and bringing new therapeutics to market. “Our relationship is meant to help combine the best available technologies.”
Imaging Endpoints will assist TD2 in the design and implementation of medical imaging analyses. Imaging Endpoints’ expertise in anatomic and functional imaging allows drug developers to best incorporate imaging into their clinical trials: probing molecular drug targets, assessing biologic responses and evaluating drug effectiveness.
“We hope that, through our new relationship with TD2, we will be able to assist oncology drug developers to maximize their return on investment in medical imaging during the course of their early-phase clinical trials,” said Dr. Ron Korn, Medical Director of Imaging Endpoints. “Significant resources and time can be saved through wise and appropriate implementation of medical imaging.”
The rapid completion of often time-consuming and costly clinical trials is needed to speed new treatments to the patients who need them, Dr. Gately said.
Imaging holds the potential to predict outcomes, shorten the time needed to evaluate if a drug is hitting its target, and do so with relatively low risk to patients. By using specific imaging techniques, researchers can assess if new drug compounds are effective in such areas as anti-proliferation, metabolism, and hypoxia.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.